An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations

References

• Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90(Suppl_1):i2–7.
   Google Scholar
• Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007–1022.
   Google Scholar
• Sasser T, Schoenfelder EN, Stein MA. Targeting functional impairments in the treatment of children and adolescents with ADHD. CNS Drugs. 2017;31:97–107.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition. [Internet]. American Psychiatric Association; 2013 [cited 2019 Feb 4]. Available from: https://dsm.psychiatryonline.org/doi/10.1176/appi.books.9780890425596.dsm01
   Google Scholar
• Xu G, Strathearn L, Liu B, et al. Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among us children and adolescents, 1997–2016. JAMA Netw Open. 2018.
   Google Scholar
• Kessler RC, Adler L, Berkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163:716–723.
   Google Scholar
• Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010;122:97–109.
   Google Scholar
• McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161:1948–1956.
   Google Scholar
• Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–270.
   Google Scholar
• Childress AC. Methylphenidate HCL for the treatment of ADHD in children and adolescents. Expert Opin Pharmacother. 2016;17:1171–1178.
   Google Scholar
• Pliszka S. AACAP work group on quality issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.
   Google Scholar
• Post RE, Kurlansik SL. Diagnosis and management of adult attention-deficit/hyperactivity disorder. Am Fam Physician. 2012;85:890–896.
   Google Scholar
• Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14–34.
   Google Scholar
• Canadian ADHD Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines. 4th ed. Toronto, Ontario; 2018.
   Google Scholar
• NICE. Attention deficit hyperactivity disorder: diagnosis and management [Internet]. 2018 [cited 2019 Sep 18]. Available from: https://www.nice.org.uk/guidance/ng87
   Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353–364.
   Google Scholar
• Hodgkins P, Shaw M, Coghill D, et al. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21:477–492.
   Google Scholar
• Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs. 2004;18:243–250.
   Google Scholar
• Maldonado R. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol. 2013;9:1001–1014.
   Google Scholar
• Markowitz JS, Patrick KS. The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27:678–689.
   Google Scholar
• Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204–211.
   Google Scholar
• Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther. 1999;66:295–305.
   Google Scholar
• López FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord. 2013;5:249–265.
   Google Scholar
• Patrick KS, Radke JL, Raymond JR, et al. Drug regimen individualization for attention-deficit/hyperactivity disorder: guidance for methylphenidate and dexmethylphenidate formulations. Pharmacotherapy. 2019;39:677–688.
   Google Scholar
• Patrick KS, González MA, Straughn AB, et al. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv. 2005;2:121–143.
   Google Scholar
• Cortese S, D’Acunto G, Konofal E, et al. New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2017;31:149–160.
   Google Scholar
• FDA. Center for drug evaluation and research: DAYTRANA clinical pharmacology and biopharmaceutics review (part 1): application number 21-514. [Internet]. 2006 [cited 2019 Mar 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021514s000_ClinPharmR_P1.pdf
   Google Scholar
• Hodgkins P, Shaw M, McCarthy S, et al. The pharmacology and clinical outcomes of amphetamines to treat ADHD. CNS Drugs. 2012;26:245–268.
   Google Scholar
• Riddle EL, Hanson GR, Fleckenstein AE. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2. Eur J Pharmacol. 2007;571:25–28.
   Google Scholar
• Stahl S. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. New York, NY: Cambridge University Press; 2013. p. 863–897.
   Google Scholar
• Dinis-Oliveira RJ. Metabolomics of methylphenidate and ethylphenidate: implications in pharmacological and toxicological effects. Eur J Drug Metab Pharmacokinet. 2017;42:11–16.
   Google Scholar
• Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999;37:457–470.
   Google Scholar
• Frölich J, Banaschewski T, Döpfner M, et al. An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Metab Toxicol. 2014;10:1169–1183.
   Google Scholar
• Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol. 2010;50:1001–1010.
   Google Scholar
• Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36:341–356.
   Google Scholar
• VYVANSE prescribing information. Lexington, MA: Shire US Inc; 2017.
   Google Scholar
• ADDERALL XR prescribing information. Lexington, MA: Shire US Inc.; 2017.
   Google Scholar
• FDA. Center for drug evaluation and research: Cotempla XR ODT clinical pharmacology and biopharmaceutics review: application number 205489Orig1s000. [Internet]. 2015 [cited 2019 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205489Orig1s000ClinPharmR.pdf
   Google Scholar
• Childress A, Newcorn J, Stark JG, et al. A single-dose, single-period pharmacokinetic assessment of an extended-release orally disintegrating tablet of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26:505–512.
   Google Scholar
• CONCERTA prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2017.
   Google Scholar
• Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS® (methylphenidate HCl) formulation. J Pharmacokinet Pharmacodyn. 2000;40:379–388.
   Google Scholar
• Wigal SB, Gupta S, Heverin E, et al. Pharmacokinetics and therapeutic effect of OROS® methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21:255–263.
   Google Scholar
• FDA. Center for drug evaluation and research: Concerta clinical pharmacology and biopharmaceutics review: application number 21-121. [Internet]. 2000 [cited 2019 Mar 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-121_Concerta_biopharmr.pdf
   Google Scholar
• Modi NB, Wang B, Hu WT, et al. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos. 2000;31:23–31.
   Google Scholar
• Modi N, Wang B, Noveck R, et al. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol. 2000;40:1141–1149.
   Google Scholar
• Pentikis HS, Simmons RD, Benedict MF, et al. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry. 2002;41:443–449.
   Google Scholar
• METADATE CD prescribing information. Smyrna, GA: UCB, Inc.; 2014.
   Google Scholar
• FDA. Center for drug evaluation and research: Metadate CD clinical pharmacology and biopharmaceutics review (part 1): application number 21-259. [Internet]. 2001 [cited 2019 Mar 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-259_Metadate_BioPharmr_P1.pdf
   Google Scholar
• FDA. Center for drug evaluation and research: Metadate CD clinical pharmacology and biopharmaceutics review (part 2): application number 21-259. [Internet]. 2001 [cited 2019 Mar 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-259_Metadate_BioPharmr_P2.pdf
   Google Scholar
• Rochdi M, González MA, Dirksen SJH. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Int J Clin Pharmacol Ther. 2004;42:285–292.
   Google Scholar
• Lee L, Kepple J, Wang Y, et al. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm Drug Dispos. 2003;24:233–243.
   Google Scholar
• Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (RITALIN® LA). Drugs. 2002;62:2251–2259.
   Google Scholar
• RITALIN LA prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019.
   Google Scholar
• FDA. Center for drug evaluation and research: RITALIN LA clinical pharmacology and biopharmaceutics review: application number 21-284. [Internet]. 2002 [cited 2019 Mar 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-284_Ritalin LA_biopharmr.pdf
   Google Scholar
• Tuerck D, Wang Y, Maboudian M, et al. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther. 2007;45:662–668.
   Google Scholar
• Tuerck D, Appel-Dingemanse S, Maboudian M, et al. Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. J Clin Pharmacol. 2007;47:64–69.
   Google Scholar
• FOCALIN XR prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.
   Google Scholar
• FDA. Center for drug evaluation and research: Focalin XR clinical pharmacology and biopharmaceutics review: application number 21-802. [Internet]. 2005 [cited 2019 Mar 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021802s000_ClinPharmR.pdf
   Google Scholar
• Moen MD, Keam SJ. Dexmethylphenidate extended release. CNS Drugs. 2009;23:1057–1083.
   Google Scholar
• Pierce D, Katic A, Buckwalter M, et al. Single-and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2010;30:554–564.
   Google Scholar
• DAYTRANA prescribing information. Miami, FL: Noven Therapeutics, LLC; 2017.
   Google Scholar
• QUILLIVANT XR Prescribing Information. Monmouth Junction, NJ: Tris Pharma, Inc.; 2017.
   Google Scholar
• Herman BK, King TR, Kando JC, et al. A novel, modified-release drug delivery technology containing amphetamine-ion exchange complexes. Poster session presented at: American Professional Society of ADHD and Related Disorders (APSARD); 2019 Jan 18–20; Washington, D.C.
   Google Scholar
• Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010;122:35–41.
   Google Scholar
• Childress AC, Sallee RF, Berry SA. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Postgrad Med. 2011;123:80–88.
   Google Scholar
• APTENSIO XR prescribing information. Coventry, RI: Rhodes Pharmaceuticals L.P.; 2016.
   Google Scholar
• Adjei A, Teuscher NS, Kupper RJ, et al. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (RITALIN®) in healthy adult volunteers. J Child Adolesc Psychopharmacol. 2014;24:570–578.
   Google Scholar
• Quinn D, Bode T, Reiz JL, et al. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J Clin Pharmacol. 2007;47:760–766.
   Google Scholar
• Adjei A, Kupper RJ, Teuscher NS, et al. Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. Clin Drug Investig. 2014;34:795–805.
   Google Scholar
• QUILLICHEW ER Prescribing Information. Monmouth Junction, NJ: Tris Pharma, Inc.; 2017.
   Google Scholar
• Abbas R, Palumbo D, Walters F, et al. Single-dose pharmacokinetic properties and relative bioavailability of a novel methylphenidate extended-release chewable tablet compared with immediate-release methylphenidate chewable tablet. Clin Ther. 2016;38:1151–1157.
   Google Scholar
• COTEMPLA XR prescribing information. Grand Prairie, TX: Neos Therapeutics, Inc.; 2017.
   Google Scholar
• Childress A, Mehrotra S, Gobburu J, et al. Single-dose pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate formulation, in healthy adults and in adolescents and children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28:10–18.
   Google Scholar
• Liu T, Gobburu JVS, Po MD, et al. Pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate: evaluation of dose proportionality, food effect, multiple-dose modeling, and comparative bioavailability with immediate-release methylphenidate in healthy adults. J Child Adolesc Psychopharmacol. 2019;29:181–191.
   Google Scholar
• JORNAY PM prescribing information. Durham, NC: Ironshore Pharmaceuticals Inc; 2018.
   Google Scholar
• Ermer JC, Adeyi BA, Pucci ML. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs. 2010;24:1009–1025.
   Google Scholar
• Quinn D, Bode T, Donnelly G, et al. Pharmacokinetics of a novel, extended release formulation of methylphenidate (PRC-063) in adolescents with ADHD and in healthy adults at steady state. Poster session presented at: American Academy of Child & Adolescent Psychiatry (AACAP) 63rd Annual Meeting; 2016 Oct 24–29; New York, NY.
   Google Scholar
• ADHANSIA XR prescribing information. Wilson, NC: Purdue Pharmaceuticals L.P.; 2019.
   Google Scholar
• Tulloch SJ, Zhang Y, McLean A, et al. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22:1405–1415.
   Google Scholar
• Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr. 2005;10:6–15.
   Google Scholar
• McGough JJ, Biederman J, Greenhill LL, et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of adderall. J Am Acad Child Adolesc Psychiatry. 2003;42:684–691.
   Google Scholar
• Kramer WG, Read SC, Tran B-V, et al. Pharmacokinetics of mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectr. 2005;10:6–13.
   Google Scholar
• FDA. Center for drug evaluation and research: Adderall XR clinical pharmacology and biopharmaceutics review: application number 21-303. [Internet]. 2001 [cited 2019 Mar 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21303_Adderall_biopharmr.pdf
   Google Scholar
• Boellner SW, Stark JG, Krishnan S, et al. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover. Clin Ther. 2010;32:252–264.
   Google Scholar
• Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: A single-dose, crossover pharmacokinetic study. J Clin Pharmacol. 2008;48:293–302.
   Google Scholar
• FDA. Center for drug evaluation and research: Vyvanse clinical pharmacology and biopharmaceutics review: application number 21-977. [Internet]. 2014 [cited 2019 Mar 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021977s000_ClinPharmR.pdf
   Google Scholar
• Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 2008;24:33–40.
   Google Scholar
• Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with adhd: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970–976.
   Google Scholar
• FDA. Center for drug evaluation and research: Vyvanse Chewable clinical pharmacology and biopharmaceutics review: application number 208510Orig1s000. [Internet]. 2017 [cited 2019 Mar 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208510Orig1s000ClinPharmR.pdf
   Google Scholar
• Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28:306–313.
   Google Scholar
• DYANAVEL XR prescribing information. Monmouth Junction, NJ: Tris Pharma, Inc; 2015.
   Google Scholar
• FDA. Center for drug evaluation and research: Dyanavel XR ODT clinical pharmacology and biopharmaceutics review: application number 208147Orig1s000. [Internet]. 2015 [cited 2019 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208147Orig1s000ClinPharmR.pdf
   Google Scholar
• Stark JG, Engelking D, McMahen R, et al. Pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;27:216–222.
   Google Scholar
• ADZENYS XR-ODT prescribing information. Grand Prairie, TX: Neos Therapeutics, Inc; 2016.
   Google Scholar
• Newcorn JH, Stark JG, Adcock S, et al. A randomized phase I study to assess the effect of alcohol on the pharmacokinetics of an extended-release orally disintegrating tablet formulation of amphetamine in healthy adults. Clin Ther. 2017;39:1695–1705.
   Google Scholar
• McMahen RL, Stark JG, Engelking D, et al. Pharmacokinetics of a novel extended-release orally disintegrating tablet amphetamine formulation under fed and fasted conditions. Poster session presented at: American Academy of Child & Adolescent Psychiatry (AACAP) 63rd Annual Meeting; 2016 Oct 24–29; New York, NY.
   Google Scholar
• ADZENYS ER prescribing information. Grand Prairie, TX: Neos Therapeutics, Inc; 2017.
   Google Scholar
• Sikes C, Stark JG, McMahen R, et al. Pharmacokinetics of a new amphetamine extended-release oral liquid suspension under fasted and fed conditions in healthy adults: a randomized, open-label, single-dose, 3-treatment study. Clin Ther. 2017;39:2389–2398.
   Google Scholar
• FDA. Center for drug evaluation and research: Adzenys ER clinical pharmacology and biopharmaceutics review: application number 204325Orig1s000. [Internet]. 2017 [cited 2019 Mar 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204325Orig1s000ClinPharmR.pdf
   Google Scholar
• Ermer JC, Shojaei A, Pennick M, et al. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin. 2007;23:1067–1075.
   Google Scholar
• MYDAYIS prescribing information. Lexington, MA: Shire US Inc; 2017.
   Google Scholar
• FDA. Center for drug evaluation and research: Mydayis clinical pharmacology and biopharmaceutics review: application number 022063Orig1s000. [Internet]. 2017 [cited 2019 Mar 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/022063Orig1s000ClinPharmR.pdf
   Google Scholar
• Braeckman R, Guenther S, Mickle TC, et al. Single- and multiple-dose pharmacokinetics of KP415, a novel d-methylphenidate product containing a prodrug of d-methylphenidate, in healthy volunteers. Poster session presented at: American Professional Society of ADHD and Related Disorders (APSARD); 2018 Jan 12–14; Washington, DC.
   Google Scholar
• Braeckman R, Guenther S, Mickle TC, et al.Dose-proportionality and steady-state pharmacokinetics of KP415, an investigational ADHD product containing Serdexmethylphenidate (SDX), a novel prodrug of d-methylphenidate. Poster session presented at: American Professional Society of ADHD and Related Disorders (APSARD); 2019 Jan 18–20; Washington DC.
   Google Scholar
• Braeckman R, Guenther S, Mickle TC, et al. Single-dose pharmacokinetics of KP415, an investigational product containing the prodrug Serdexmethylphenidate (SDX), in children and adolescents with ADHD. Poster session presented at: American Professional Society of ADHD and Related Disorders (APSARD); 2019 Jan 18–20; Washington DC.
   Google Scholar
• Abele S, Silva R, Brams M, et al. Development and in vivo pharmacoscintigraphic evaluation of a novel triple-release dexmethylphenidate hydrochloride tablet for improved once daily dosing. Poster session presented at: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting; 2017 Nov 12–15; San Diego, CA.
   Google Scholar
• Silva R, Brams M, Straughn A, et al. Pharmacoscintigraphic and pharmacokinetic analysis of CTx-1301, a novel tri-modal oral formulation for release of dexmethylphenidate in healthy adults. Poster session presented at: American Professional Society of ADHD and Related Disorders (APSARD); 2018 Jan 12–14; Washington, DC.
   Google Scholar
• Childress A, Tran C. Current investigational drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2016;25:463–474.
   Google Scholar
• Quinn D, Bode T, De Sousa B, et al. A phase 2 pharmacokinetic study of a modified release formulation of dextroamphetamine following evening administration to adolescents and children with ADHD. Poster session presented at: 5th World Congress on ADHD; 2015 May 28–31; Glasgow, Scotland.
   Google Scholar
• Herman BK, Kando JC, King TR, et al. Single-dose pharmacokinetics of amphetamine extended-release tablet compared with amphetamine extended-release oral suspension. Poster session presented at: American Academy of Child & Adolescent Psychiatry (AACAP) 65th Annual Meeting; 2018 Oct 22–27; Washington, DC.
   Google Scholar
• Gomeni R, Bressolle-Gomeni FMM, Spencer TJ, et al. Model-based approach for optimizing study design and clinical drug performances of extended-release formulations of methylphenidate for the treatment of ADHD. Clin Pharmacol Ther. 2017;102:951–960.
   Google Scholar
• Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476–495.
   Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the comacs study). Pediatrics. 2004;113:e206–e216.
   Google Scholar
• Sonuga-Barke EJ, Swanson JM, Coghill D, et al. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry. 2004;4:28.
   Google Scholar
• Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(Suppl 1):S31–43.
   Google Scholar
• Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160:1909–1918.
   Google Scholar
• Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res. 2002;130:73–78.
   Google Scholar
• Coghill D, Banaschewski T, Zuddas A, et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13:237.
   Google Scholar
• Volkow ND, Wang G-J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325–1331.
   Google Scholar
• Gomeni R, Fang LL, Bressolle-Gomeni F, et al. A general framework for assessing IVIVC as a tool for maximizing the benefit-risk ratio of a treatment using a convolution-based modeling approach. CPT Pharmacometrics Syst Pharmacol. 2019.
   Google Scholar
• Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010;19:325–340.
   Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 2003;23:1281–1299.
   Google Scholar
• Steingard R, Taskiran S, Connor DF, et al. New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019;29:1–16.
   Google Scholar
• FDA. Center for drug evaluation and research: Adzenyz XR-ODT clinical pharmacology and biopharmaceutics review: application number 204326Orig1s000. [Internet]. 2016 [cited 2019 Mar 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204326Orig1s000ClinPharmR.pdf
   Google Scholar
• FDA. Center for drug evaluation and research: Aptensio XT clinical pharmacology and biopharmaceutics review: application number 205831Orig1s000. [Internet]. 2015 [cited 2019 Mar 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205831Orig1s000ClinPharmR.pdf
   Google Scholar
• FDA. Center for drug evaluation and research: Jornay PM clinical pharmacology and biopharmaceutics review: application number 209311Orig1s000. [Internet]. 2018 [cited 2019 Mar 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209311Orig1s000ClinPharmR.pdf
   Google Scholar
• FDA. Center for drug evaluation and research: Quillichew ER clinical pharmacology and biopharmaceutics review: application number 207960Orig1s000. [Internet]. 2015 [cited 2019 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207960Orig1s000ClinPharmR.pdf
   Google Scholar
• FDA. Center for drug evaluation and research: Quillivant XR clinical pharmacology and biopharmaceutics review: application number 202100Orig1s000. [Internet]. 2012 [cited 2019 Mar 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202100Orig1s000ClinPharmR.pdf
   Google Scholar
• Warshaw EM, Paller AS, Fowler JF, et al. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin Ther. 2008;30(2):326–327.
   Google Scholar
• Wigal SB, Gupta S, Greenhill L, et al. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17:153–164.
   Google Scholar
• Zhu HJ, Patrick KS, Yuan HJ, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82:1241–1248.
   Google Scholar
• Zhu H-J, Patrick KS, Straughn A, et al. Ethanol interactions with dexmethylphenidate and dl-methylphenidate spheroidal oral drug absorption systems in healthy volunteers. J Clin Psychopharmacol. 2017;37:419–428.
   Google Scholar
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727–738.
   Google Scholar
• Duong S, Chung K, Wigal SB. Metabolic, toxicological, and safety considerations for drugs used to treat ADHD. Expert Opin Drug Metab Toxicol. 2012;8:543–552.
   Google Scholar
• Childress A. The safety of extended-release drug formulations for the treatment of ADHD. Expert Opin Drug Saf. 2017;16:603–615.
   Google Scholar
• Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;11:CD009885.
   Google Scholar
• Storebø OJ, Krogh HB, Ramstad E, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.
   Google Scholar
• Punja S, Shamseer L, Hartling L, et al. Amphetamines for ADHD in children and adolescents (review). Cochrane Database Syst Rev. 2016;2:CD009996.
   Google Scholar
• Gandhi A, Beekman C, Parker R, et al. Novel and rapid LC-MS/MS method for quantitative analysis of methylphenidate in dried blood spots. Bioanalysis. 2018;10:839–850.
   Google Scholar
• Kimko H, Gibiansky E, Gibiansky L, et al. Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis. J Pharmacokinet Pharmacodyn. 2012;39:161–176.
   Google Scholar
• Teuscher NS, Sikes CR, McMahen R, et al. Population pharmacokinetic-pharmacodynamic modeling of a novel methylphenidate extended-release orally disintegrating tablet in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2018;38:467–474.
   Google Scholar
• Teuscher NS, Adjei A, Findling RL, et al. Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. Drug Des Devel Ther. 2015;9:2767–2775.
   Google Scholar
• Gomeni R, Faraone SV, Spencer TJ, et al. Establishing clinical benefit of HLD200, a novel delayed-release and extended-release formulation of methylphenidate, using a model-based approach. Poster session presented at: American Professional Society of ADHD and Related Disorders (APSARD); 2017 Jan 14; Washington, DC.
   Google Scholar